Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Simurosertib |
Synonyms | |
Therapy Description |
Simurosertib (TAK-931) inhibits CDC7, potentially resulting in decreased tumor growth (J Clin Oncol 36, 2018 (suppl; abstr 2506), PMID: 31131319). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Simurosertib | TAK-931|TAK931|TAK 931 | CDC7 Inhibitor 4 | Simurosertib (TAK-931) inhibits CDC7, potentially resulting in decreased tumor growth (J Clin Oncol 36, 2018 (suppl; abstr 2506), PMID: 31131319). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03261947 | Phase II | Simurosertib | A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors | Completed | USA | 1 |